



# Implanted haemodynamic telemonitoring devices to guide management of heart failure: a review and meta-analysis of randomised trials

Antonio Iaconelli<sup>1,2</sup> · Pierpaolo Pellicori<sup>1</sup> · Elisabetta Caiazzo<sup>3,4</sup> · Asma O. M. Rezig<sup>3</sup> · Dario Bruzzese<sup>5</sup> · Pasquale Maffia<sup>3,4</sup> · John G. F. Cleland<sup>1</sup>

Received: 2 June 2022 / Accepted: 6 September 2022 / Published online: 14 October 2022  
© The Author(s) 2022

## Abstract

**Background and aims** Congestion is a key driver of morbidity and mortality in heart failure. Implanted haemodynamic monitoring devices might allow early identification and management of congestion. Here, we provide a state-of-the-art review of implanted haemodynamic monitoring devices for patients with heart failure, including a meta-analysis of randomised trials.

**Methods and results** We did a systematic search for pre-print and published trials in Medline, Embase, and the Cochrane Central Register of Controlled Trials (CENTRAL) on the 22nd of September 2021. We included randomised trials that compared management with or without information from implanted haemodynamic monitoring devices for patients with heart failure. Outcomes selected were hospitalisation for heart failure and all-cause mortality. Changes in treatment associated with haemodynamic monitoring resulted in only a small reduction in mean pulmonary artery pressure (typically < 1 mmHg as a daily average), which generally remained much greater than 20 mmHg. Haemodynamic monitoring reduced hospitalisations for heart failure (HR 0.75; 95% CI 0.58–0.96;  $p=0.03$ ) but not mortality (RR 0.92; 95% CI 0.68–1.26;  $p=0.48$ ).

**Conclusions** Haemodynamic monitoring for patients with heart failure may reduce the risk of hospitalization for heart failure but this has not yet translated into a reduction in mortality, perhaps because the duration of trials was too short or the reduction in pulmonary artery pressure was not sufficiently large. The efficacy and safety of aiming for larger reductions in pulmonary artery pressure should be explored.

---

✉ Antonio Iaconelli  
Antonio.Iaconelli@glasgow.ac.uk

<sup>1</sup> School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, UK

<sup>2</sup> Department of Cardiovascular Medicine, Fondazione Policlinico Universitario A. Gemelli IRCCS, 00168 Rome, Italy


<sup>3</sup> School of Infection and Immunity, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, UK

<sup>4</sup> Department of Pharmacy, School of Medicine and Surgery, University of Naples Federico II, Naples, Italy

<sup>5</sup> Department of Public Health, School of Medicine and Surgery, University of Naples Federico II, Naples, Italy

## Graphical abstract

## Implanted haemodynamic telemonitoring devices to guide management of heart failure: a review and meta-analysis of randomised trials



After selecting key words, a systematic review for implanted haemodynamic telemonitoring devices was performed in different dataset and 4 randomised clinical trials were identified and included in this meta-analysis. Three different devices (Chronicle, Chronicle/ICD and CardioMEMS) were tested. All-cause mortality and total heart failure hospitalisations were selected as outcomes. No reduction in all-cause mortality rate was reported but a potential benefit on total heart failure hospitalisation was identified.

**Keywords** Tele-monitoring · Pulmonary hypertension · Implantable devices · Heart failure

### Abbreviations

ACE-I/ARBs	Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers
FDA	Food and Drug Administration
HF <sub>r</sub> EF	Heart failure with reduced ejection fraction
HF <sub>p</sub> EF	Heart failure with preserved ejection fraction
HR	Hazard ratio
ICD	Implantable cardioverter defibrillator
NYHA	New York Heart Association
PA	Pulmonary artery
PAP	Pulmonary artery pressure
PAP <sub>d</sub>	Pulmonary artery diastolic pressure
ePAP <sub>d</sub>	Estimated pulmonary artery diastolic pressure
PAP <sub>m</sub>	Pulmonary artery mean pressure
PAP <sub>s</sub>	Pulmonary artery systolic pressure
PCWP	Pulmonary capillary wedge pressure
PH	Pulmonary hypertension
RHC	Right heart catheterisation

RR	Risk ratio
RV	Right ventricle
SGLT2-Is	Sodium glucose cotransporter-2 inhibitors
TR	Tricuspid regurgitation

### Introduction

Heart failure can be defined as cardiac dysfunction associated with interstitial or intravascular water and salt retention, otherwise known as congestion. Congestion is not only a cause of symptoms and signs but may also cause cardiac dysfunction, remodelling and arrhythmias, which are all associated with a poorer prognosis [1]. Identifying, quantifying and treating congestion at an early stage is a key task for good management of heart failure, but it is currently done sub-optimally.

Symptoms and signs have traditionally been used to guide therapy but are not specific for heart failure and may only be obvious once decompensation is severe [2]. High plasma

concentrations of natriuretic peptides correlate with symptoms and with the severity of cardiac dysfunction [1] and are associated with an increased risk of hospitalisation and death due to heart failure; although measurement of natriuretic peptides facilitates initial diagnosis, their serial evaluation has not been shown—convincingly—to improve heart failure management [3]. The requirement for more than a drop of blood for point-of-care measurement makes monitoring by patients at home difficult [4].

Echocardiography is not only widely available and frequently used for non-invasive, real-time assessment of cardiac structure and function but can also provide information on congestion. However, it requires expertise to acquire and interpret images, and there is little evidence, as yet, that serial ultrasound can be used to guide diuretic treatment. There is also a lack of robust evidence that other non-invasive approaches to estimate the amount of body water and its distribution, such as weighing scales, bio-impedance or remote dielectric sensing, improve management and outcomes for patients with heart failure [5].

Elevated pulmonary artery (PA) or right ventricular pressures also reflect congestion and identify patients with heart failure who are at greater risk of hospitalization or death [6]. Recently, implantable miniaturised sensors have been developed and tested to assist clinicians in the management of patients with symptomatic heart failure, allowing treatments to be haemodynamically tailored for each patient individually in the hope that this will improve well-being, reduce hospitalisation and, hopefully, increase longevity [7].

In this manuscript, we summarise the rationale and the current state-of-the-art of implanted haemodynamic monitoring devices for patients with heart failure. We also conducted a systematic review and meta-analysis of randomised trials to investigate the effects of this strategy on heart failure hospitalisations and mortality in this population.

## **Pulmonary hypertension and heart failure: a vicious circle**

Recently, updated guidelines reduced the threshold for diagnosing PH from a mean PAP of 25 mmHg down to 20 mmHg, assessed at rest during a right heart catheterisation (RHC) [8]. However, the median value for a resting PAPm in a healthy population is approximately 15 mmHg, with a normal range of about 11–17 mmHg [9]. Data from a broad range of patients, mostly men, in the VA-CART programme (> 20,000 patients, 97% men, 2473 with heart failure) found that the risk of hospitalisation and mortality starts to increase, progressively, when an invasively measured PAPm exceeds 19 mmHg [10].

In routine clinical practice, ultrasound is often used to identify PH, combining information from tricuspid

regurgitation (TR) peak velocity and inferior vena cava diameter and collapsibility to estimate PA systolic pressure (PAPs) [11]; an echocardiogram will also help identify causes of PH, such as mitral valve or left ventricular disease. PAPs measured by ultrasound generally correlate well with invasively measured values [12]. However, peak TR velocity may underestimate PAPs when tricuspid regurgitation is severe or in case of right ventricular dysfunction, necessitating invasive assessment to confirm a diagnosis or quantify the severity of PH [8].

Persistently elevated left atrial pressures, due to left ventricular dysfunction or mitral valve disease, are transmitted backwards to the pulmonary circulation, leading to a rise of pulmonary artery pressure (PAP) [13]. At first, PA pressures may be largely dictated by left atrial pressure, rising only with exercise or episodes of decompensation. However, over time, increases in pulmonary vascular tone and hypertrophy of the pre-capillary pulmonary vascular smooth muscle may develop. Pathophysiologically, this may protect the pulmonary capillaries from increases in pulmonary arterial, although not pulmonary venous, pressure. Eventually, vascular remodelling may lead to relatively fixed pulmonary hypertension that is independent of left atrial pressure and may be relatively unresponsive to pulmonary vasodilators, which may even have deleterious effects by increasing perfusion to poorly aerated lung regions (ventilation perfusion mismatch) [14–16]. An elevated PAP increases the load on the right ventricle (RV), which may cause dilation and dysfunction, leading to tricuspid regurgitation and increasing systemic venous congestion. Once this happens, the risk of decompensation, hospital admission and death increases substantially [17, 18].

PH is common in patients with heart failure, but its reported prevalence depends on the criteria used to define it and the severity of heart failure [19–21]. Perhaps all patients with chronic heart failure have some PH and it is not really a question of prevalence but only of severity. For most patients with heart failure, the severity of PH at rest is mild. A study in a broad population of heart failure, defining PH as a PAPs of > 45 mmHg by ultrasound, suggested a prevalence of PH less than 10% [6, 22]. Defining PH as a PAPs  $\geq$  35 mmHg provides much higher estimates of prevalence ranging from about 30–50% amongst patients with heart failure and preserved left ventricular ejection fraction (HFpEF) [6, 17, 23, 24]. Similarly, a series of reports suggests that most patients with heart failure and reduced ejection fraction (HFrEF) have PH, with the prevalence varying by the stringency of the diagnostic criteria for PH [20, 25–28] (Table 1).

Patients with PH generally have more severe heart failure, are older [23, 29] and are more likely to have atrial fibrillation [20, 23, 26, 28], poorer renal function [20, 25], higher plasma concentrations of natriuretic peptides [20, 25] and to be treated with loop diuretics [6, 20, 22, 25] (Table 1).

**Table 1** Prevalence of pulmonary hypertension in cohorts or trials of patients with heart failure

	Ghio [26]	Damy [6]	Miller [20]	CHAMPION [38]	Aronson [25]	Lam [29]	Leung [23]	GUIDE-HF [37]	REDUCE-LAP [27]
Year of publication	2001	2010	2013	2011	2013	2009	2010	2021	2022
Country	Italy	UK	US	US	Israel	US	US	US and Canada	International
Number of patients	377	1380	463	550	326	203	455	1000	570
Clinical setting	Outpatients	Outpatients	Outpatients	Mixed	Inpatients	Mixed	Mixed	Mixed	
HFrEF (%)	100	74	100	78	47	0	0	53	0
Diagnostic method	RHC	Doppler	RHC	RHC	Doppler	Doppler	RHC	RHC	RHC
Criteria adopted (mmHg)	PAPm >20	RVTG >35	PAPm ≥25	PAPm ≥25	PAPs > 50	PAPs >35	PAPm >25	PAPm ≥25	PVR ≥1.74 WU*
Patients with PH, n (%)	236 (62)	102 (7)	337 (73)	314 (60)	139 (43)	169 (83)	239 (52)	687 (69)**	PVD: 188 (33)*
<b>Key characteristics of patients with (or without) pulmonary hypertension</b>									
<i>Demographics</i>									
Age (years)	51 (vs 51)	73 (vs 74)	59 (vs 57)	62 (vs 61)	75 (vs 76)	79 (vs 74)	68 (vs 65)		73 (vs 70)
Men (%)	87 (vs 81)	66 (vs 61)	75 (vs 69)	72 (73)	48 (vs 42)	41 (vs 47)	50 (vs 51)		37 (vs 40)
AF (%)	21 (vs 16)	42 (vs 48)	45 (vs 37)	52 (vs 39)	43 (vs 41)	31 (vs 22)	22 (vs 8)		79 (vs 57)
SBP (mmHg)			113 (vs 110)	121 (vs 123)		134 (vs 125)			
<i>Blood tests</i>									
Creatinine (mg/dl)			1.6 (vs 1.4)	1.4 (vs 1.3)	1.7 (vs 1.5)		1.06 (vs 0.99)		
eGFR (mL/min/1.73 m <sup>2</sup> )		55 (vs 59)	53 (vs 59)	59 (vs 64)	46 (vs 53)				55 (vs 56)
BNP in patients with AF (pg/ml)									248 (vs 196)
BNP in patients without AF (pg/ml)									127 (vs 79)
NT-proBNP (pg/ml)		3647 (vs 1430)							
NT-proBNP in patients with AF (pg/ml)									1241 (vs 881)
NT-proBNP in patients without AF (pg/ml)									413 (269)
Haemoglobin (g/dl)		13.1 (vs 13.2)	12.7 (vs 13.2)						
<i>Therapy</i>									
BBs (%)			91 (vs 95)		75 (vs 65)				74 (vs 69)
ACE-I or ARBs (%)			82 (vs 74) <sup>a</sup>		65 (vs 64)				64 (vs 61)
MRAs (%)					24 (vs 15)				49 (vs 53)
Diuretics (%)			96 (vs 86)		90 (vs 85)				85 (vs 80)
Loop diuretic dosage (mg)	102 (vs 54)								51 (vs 55)

ACE-I/ARBs angiotensin-converting enzyme inhibitors and angiotensin receptor blockers, AF atrial fibrillation, BBs beta-blockers, BNP B-type natriuretic peptides, eGFR estimated glomerular filtration rate, HFrEF heart failure with reduced ejection fraction, MRAs mineralocorticoid antagonists, NT-proBNP amino-terminal pro-brain natriuretic peptide, PAPm pulmonary artery mean pressure, PAPs pulmonary artery systolic pressures, PH pulmonary hypertension, PVD pulmonary vascular disease, PVR pulmonary vascular resistance, RHC right heart catheterization, RVTG right ventricular tricuspid gradient, SBP systolic blood pressure, UK United Kingdom, US United States

<sup>a</sup>Patients with pulmonary vascular disease are defined as PVR ≥ 1.74 WU at 20 W of exercise, measured prior to the randomisation

<sup>b</sup>The prevalence rate of PH in the GUIDE-HF is not provided by the authors: the value reported in this table is an estimate obtained considering the average of PAPm, the standard deviation and the number of specimens of the study population, assuming a normal distribution

<sup>c</sup>This data refers only to ACE-I. Data are reported as n (%) and mean. Data on the REDUCE-LAP section are reported as n (%) and median

Indeed, patients who do not have distinctly elevated plasma concentrations of natriuretic peptides often do not have sufficient tricuspid regurgitation to measure velocities accurately and do not appear to have PH. In other words, plasma natriuretic peptides can be effectively used to exclude the presence of PH in clinical practice [6]. Both for patients with HFrEF and HFpEF, increasing PAP is associated with a poorer prognosis [20, 24].

## Monitoring pulmonary artery pressure: a new approach for heart failure management

The ESCAPE trial [30] investigated whether invasive haemodynamic monitoring—target pulmonary capillary wedge pressure (PCWP) of 15 mmHg and right atrial pressure of 8 mmHg—would improve outcome compared to clinical assessment alone for patients hospitalised with heart failure. The results were disappointing; haemodynamic monitoring did not increase days alive out of hospital or

reduce plasma concentrations of B-type natriuretic peptides. A subsequent meta-analysis conducted to assess the impact of invasive haemodynamic assessment by pulmonary artery catheter on the management of critically ill patients (13 studies, > 5000 patients, including those enrolled in the ESCAPE trial), suggested no clinical benefit [31].

## The chronicle device [32]

The Chronicle device had a lead-mounted pressure sensor placed in the outflow tract of the RV. The lead was connected to a box, implanted subcutaneously in the pectoral area and containing the electronic components and power source. The pressure sensor used the principle of variable capacitance to provide measures of RV systolic and diastolic pressures and to assess the maximum rate of the pressure increase and decrease (max  $dP/dt$ ) used to estimate the pulmonary artery diastolic (ePAPd) pressure that closely correlated with the pulmonary artery diastolic pressure (PAPd), measured invasively. A handheld radiofrequency wand, placed over the chest by the patient, interrogated the device and transmitted

data remotely to healthcare professionals for review. Initially developed as a stand-alone device, the technology was subsequently incorporated into an implantable cardioverter defibrillator (ICD). The device measured pressures continuously but stored only a sample in memory that could be transmitted; this was usually the 8.5 min prior to each transmission. Patients could be instructed to rest or take exercise prior to transmitting data.

### Chronicle ICD system [33]

This device represented an evolution of the Chronicle, with the pressure-sensing system incorporated into an ICD. A single-chamber ICD lead was placed in the RV apex and an additional lead positioned in the RV outflow tract to measure pressures.

### CardioMEMS system [34]

CardioMEMS measures PAP using micro-electromechanical system (MEMS) technology and requires neither batteries nor leads. The sensor is 15-mm long and 3-mm wide and is permanently implanted in a distal branch of the PA via RHC. Two loops at the ends of the sensor serve as anchors and allow automatic sizing to the width of the vessel. The PA sensor consists of a three-dimensional coil and pressure sensitive capacitor. The coil electromagnetically couples the pressure sensitive capacitor to the electronics system, allowing the remote measurement of the resonant frequency then it is converted to a pressure measurement. Collection of haemodynamic data requires the patient to lie on an external pillow-like device which injects radiofrequency energy into the sensor, receives back signals to generate the waveform and transmits the data to a remote service facility that then relays the results to the patient's healthcare provider. Only a few minutes of PA pressures are transmitted. Thus, although the sensor is always exposed to PA pressures, it is not currently possible to obtain 24 h pressures.

Compared to the Chronicle device, CardioMEMS does not require a surgical implantation procedure with the entailed risks and complications; CardioMEMS also measures PA pressure directly. However, a potential limitation of CardioMEMS is the difficulty in capturing data during exercise. Assessing PA pressure during exercise might detect sub-optimal control of congestion at an earlier stage.

## Systematic review and meta-analysis

In symptomatic patients with heart failure, monitoring of PAP using a wireless haemodynamic monitor system has been assigned a class IIb recommendation (level of evidence

B) by the 2021 European Society of Cardiology (ESC) heart failure guidelines [35] in order to improve clinical outcomes. The current guidelines on heart failure, provided by the AHA/ACC/HFSA [36], were recently updated. Consistent with ESC guidelines, they assigned a class IIb recommendation for the use of PAP haemodynamic monitors, but they restricted this indication only to the patients in New York Heart Association (NYHA) functional class III who had previously been hospitalised for heart failure or had elevated plasma concentrations of natriuretic peptides. They also highlighted that PAP monitoring was of uncertain benefit in reducing the risk of subsequent heart failure hospitalisation. Earlier in 2022, the US Food and Drug Administration (FDA) extended the indications for the CardioMEMS PA pressure monitor to include patients with heart failure 'who have either been hospitalized for heart failure in the previous year and/or have elevated natriuretic peptides', opening the way to more widespread use of this technology.

To further evaluate the validity of these recommendations, we conducted a meta-analysis (graphical abstract) after the publication of the largest trial to date, GUIDE-HF trial [37].

Our primary and secondary outcomes were total heart failure hospitalisations and all-cause mortality, respectively. Full methods are shown in the supplementary material. Briefly, on the 22nd of September 2021, we searched Medline (PubMed), Embase (Ovid) and the Cochrane Central Register of Controlled Trials (CENTRAL) databases for randomised trials that investigated the use of implantable haemodynamic systems to monitor PAP in patients with heart failure.

Only fully peer-reviewed manuscripts written in English were considered for inclusion. After removing duplicates ( $n = 406$ ), a further 4818 records were excluded by screening titles and abstracts; the remaining 431 articles were fully evaluated. We finally identified eight papers from four clinical trials: the CardioMEMS Heart Sensor Allows Monitoring of Pressure to Improve Outcomes in NYHA Class III Heart Failure Patients (CHAMPION, four papers) [38–41], the Chronicle Offers Management to Patients with Advanced Signs and Symptoms of Heart Failure (COMPASS-HF, two papers) [42, 43], the Reducing Decompensation Events Utilizing Intracardiac Pressures in Patients With Chronic Heart Failure (REDUCEhf, one paper) [44] and the haemodynamic-GUIDEd management of Heart Failure (GUIDE-HF, one paper) [37]. Figure 1 shows the results of our search strategy (PRISMA flow diagram), whilst table S1 (supplementary material) summarises the baseline characteristics of enrolled populations. All the trials we found were conducted in North America between 2008 and 2021 and all patients enrolled had a monitoring device implanted, regardless of allocation; however, the information acquired by the sensors were disclosed to physicians only for patients in the intervention arm. A key strategy that differentiated the design

of CHAMPION and GUIDE-HF was the introduction of specific algorithms that guided the clinicians on the implementation of therapy according to haemodynamic readings. More detailed information about these trials are summarised in Table 2. Overall, compared to standard care, the use of implanted haemodynamic sensors reduced the risk of total heart failure hospitalisation by 25% (2224 patients; HR 0.75; 95% CI 0.58–0.96;  $p=0.03$ ) (Fig. 2A), using data from the longest follow-up available, but was not associated with a reduction in the risk of all-cause mortality (RR 0.92; 95% CI 0.68–1.26;  $p=0.48$ ) (Fig. 2B).

## Discussion

Considering the cost and complexity of haemodynamically guided monitoring for patients with heart failure, the results of randomised trial conducted, so far, are rather disappointing. Although haemodynamic monitoring might reduce hospitalisations for heart failure, the confidence intervals around the estimate are wide and the statistical certainty low. There are many potential explanations for why a reduction in hospitalisations and PA pressure might not translate into a reduction in mortality. Longer follow-up might be required for such small reductions in PA pressure to translate into reductions in mortality; more intense management to normalise PA pressure might lead to a greater reductions in hospitalisations and mortality but with the risk of more side effects. Perhaps the therapeutic algorithms are too cautious; perhaps current treatments are just not sufficiently effective [45, 46].


In order to improve management of heart failure by haemodynamic monitoring, measurements should be accurate in order to avoid false alerts and detect true ones and must be followed by changes in management to correct the perceived problem (a low or a high PA pressure). The optimal target PAP may differ from one patient to the next. A too low pressure due to intensification of heart failure therapy may lead to a fall in cardiac output, systemic arterial pressures and renal function. Patient engagement is essential. Unless patients are given the correct advice and follow management recommendations, haemodynamic monitoring will not be of any help. There is a long ‘delivery chain’ including the sensor, the patient taking the measurement, transmission to the service centre, relay on to the care team, the formulation of recommendations by the care team, the transmission of those recommendations back to the patient and the patient acting on the advice. There is a lot that could go wrong: the chain is only as strong as its weakest link.

In the COMPASS-HF [42] trial, heart failure therapies, particularly loop diuretics, were adjusted more frequently in patients assigned to the haemodynamic-guided arm than controls but trialists did not define an ePAPd target

of treatment and, as a consequence, the mean ePAPd of the whole population remained high, at around  $28 \pm 7$  mmHg throughout the entire study [42–44], suggesting either that investigators failed to recommend more intense treatment or that patients did not or could not (due to side effects) implement it. This failure is important, as a retrospective analysis using pooled data from three studies of the Chronicle programme ( $n=790$  patients) suggests that only a substantial reduction in ePAPd during follow-up reduced mortality; however, a decrease of 3 mmHg, or more, between baseline and 6 months was observed in less than 20% of patients [47–49].

In CHAMPION [38], haemodynamic-guided therapy was associated with a 28% reduction in heart failure hospitalisations, compared to the control group, during 6 months of follow-up, with similar encouraging results considering data from the entire follow-up (mean 18 months). CHAMPION provided instructions to investigators on how to modify treatment, mainly diuretics—followed by vasodilators, to achieve pre-specified ‘optimal’ haemodynamic readings. During follow-up, not only diuretics and vasodilators but also other neuro-hormonal antagonist therapies were adjusted more frequently in those assigned to active monitoring [39, 47]. Rather than responding to measurements thought to reflect an imminent problem, CHAMPION investigators attempted to adjust treatment constantly to maintain PAP as close to ideal as possible [50]. However, treatment guided by haemodynamic monitoring reduce PAPm by only ~5% in relative terms and only – 1.6 mmHg in absolute terms compared to no changes observed in the control group. Findings from CHAMPION also confirmed the close relationship between PH and adverse outcome [38]. Of the 537 patients enrolled and with complete baseline haemodynamic data, the 320 (59%) who met the criteria of Group II PH [8] had a higher rate of heart failure hospitalisations and greater risk of death than those without PH.

GUIDE-HF is the largest trial of haemodynamic monitoring conducted so far. By design, each patient was to be followed for only 12 months. Investigators were asked to contact participants twice a month for the first 3 months and then monthly until the end of the trial. Haemodynamic monitoring may provide less benefit when clinical care in the control group is frequent and of a high quality. Unfortunately, the COVID-19 pandemic struck when only about 40% of patients had completed 12 months of follow-up. An analysis [51] comparing findings prior and after the spread of COVID-19 pandemic was published recently, after our systematic search. The GUIDE-HF trial appeared to be on course for a positive result consistent with CHAMPION prior to COVID but then something remarkable happened. With the advent of COVID, PA pressures improved in the control group to the same extent as the intervention group. It appears that patients with heart failure during COVID might



**Fig. 1** The identification process of the studies. PRISMA flow diagram of the studies retrieval and selection process used

have become more adherent to their treatments and may have modified their lifestyle. Once the difference in pressures was lost, so was the difference in event rates. In a sense, this proves that better control of PA pressures is effective but questions whether we need frequent haemodynamic monitoring to achieve it. Perhaps monitoring every few months by a non-invasive approach, such as ultrasound, would be similarly effective. However, the reduction in PA pressures even prior to COVID was modest [45]. Both CHAMPION and GUIDE-HF show that we need more effective means of controlling PAP, either better implementation of existing interventions or new treatments.

The rate of hospitalisation in CHAMPION and GUIDE-HF appears to be much higher, both in the intervention group and in the control arm, compared to many other landmark trials of heart failure (Table S3, supplementary material). Differences in the characteristics of the population, in the design of the trial or the number of contacts between patients and physicians, during follow-up, both in the treatment and control arms, could explain the high rates of hospitalisation. Patients in GUIDE-HF may have been in a worse functional class than most other trials and had poorer renal function but they did not have a higher plasma NT-proBNP or annual mortality.

Although many patients with elevated PAP must have been enrolled in landmark trials of beta-blockers and

angiotensin-converting enzyme inhibitors and angiotensin receptor blockers (ACE-I/ARBs), the effects of these therapies on PAP have been rarely evaluated. In animal models, mineralocorticoid receptor antagonists improve RV function and reverse PH, but studies in patients with heart failure and PH are lacking [52]. Indeed, no trial has ever evaluated the effects of loop diuretics on pulmonary pressures, even if they are the most commonly used drugs to decongest patients with evidence of elevated PAP.

Tran and colleagues [53] reported a rapid fall in mean ( $-3.6$  mmHg), systolic ( $-6.5$  mmHg) and diastolic ( $-2.5$  mmHg) PA pressures when treatment with ACE-I/ARBs was switched to sacubitril/valsartan in 18 patients with HFrEF with a CardioMEMS implant. Consistent with these results, Khan and colleagues [54] reported a reduction in PAPd ( $-2.5$  mmHg), PAPs ( $-3.6$  mmHg) and PAPm ( $-3.2$  mmHg) following initiation of treatment with sacubitril/valsartan in 13 patients with HFrEF who also had been implanted with a CardioMEMS device.

Sodium glucose cotransporter-2 inhibitors (SGLT2-Is) have recently been shown to be highly effective for the treatment of heart failure [55]. In a single-centre observational study, dapagliflozin reduced CardioMEMS PAPm from  $42 \pm 9$  to  $38 \pm 10$  mmHg, after seven days from initiation of the treatment [56]. In the EMBRACE-HF trial [57], 65 patients with heart failure (mean age 66 years, 97% on loop diuretics) and a CardioMEMS system (mean PAPd 22 mmHg) were randomised to empagliflozin or placebo. Compared to those assigned to placebo, empagliflozin 10 mg/day reduced the PAPd (averaged between 8 and 12 weeks, primary endpoint) by  $\sim 1.5$  mmHg, regardless of heart failure phenotype. A greater proportion of patients assigned to empagliflozin also achieved a  $\geq 20\%$  reduction in plasma amino-terminal pro-brain natriuretic peptide values at 12 weeks (34% versus 7%;  $p=0.01$ ).

The real-world clinical experience with CardioMEMS provides the opportunity to evaluate the combined effects of intensification of treatment on PAP in patients with heart failure but also the long-term safety of this approach. Using data from a post-approval registry of 1200 patients with severe heart failure symptoms implanted with CardioMEMS, Shavelle and colleagues [58] showed that intensification of medications reduced PAPm during 1 year of observation in those with baseline PAPm  $\geq 35$  mmHg ( $-4.8 \pm 6.2$  mmHg), but when PAPm was  $< 25$  mmHg at baseline, pressures rose ( $+1.5 \pm 5.8$  mmHg). Patients with a baseline PAPm of 25–34 mmHg had an intermediate response ( $-1.3 \pm 5.0$  mmHg).

These findings replicate those previously reported by Heywood and colleagues [59], who used de-identified PAP data from the first 2000 patients with heart failure implanted with a CardioMEMS who had at least 6 months of follow-up. They found that patients with a

**Table 2** Key characteristics of the trials included in the meta-analysis

TRIAL (Year of publication)	COMPASS-HF [42,43] (2008)	REDUCE <sub>HF</sub> [44] (2011)	CHAMPION [38–41] (2011)	GUIDE-HF [37] (2021)
<b>Device used</b>	Chronicle	Chronicle-ICD	CardioMEMS	CardioMEMS
<b>Country (Enrolling Sites)</b>	US (28)	US (53)	US (64)	US and Canada (118)
<b>Patients (intervention:control)</b>	274 (134:140)	400 (202:198)	550 (270:280)	1000 (497:503)
<b>Control</b>	Standard of care	Standard of care	Standard of care	Standard of care
<b>Follow up length</b>	6 months	12 months	6 months	12 months
<b>Scheduled visits</b>	1,3 and 6 months	1,3,6,9 and 12 months	1, 3 and 6 months	6 and 12 months
<b>Blinding</b>	Single blind <sup>a</sup>	Single blind <sup>a</sup>	Single blind <sup>a</sup>	Single blind <sup>a</sup>
<b>Main inclusion criteria</b>				
<b>Functional class</b>	NYHA III-IV	NYHA II-III	NYHA III	NYHA II-IV
<b>Previous HFH</b>	Within 6 months	Within 12 months	Within 12 months	Within 12 months
<b>Others</b>	-	ICD indication	-	Elevated natriuretic peptides*
<b>Main exclusion criteria</b>				
<b>CKD</b>	Creatinine ≥ 3.5 mg/dL	eGFR < 30 mL/min/1.73m <sup>2</sup>	eGFR < 25 mL/min/1.73m <sup>2</sup>	eGFR < 25 mL/min/1.73m <sup>2</sup>
<b>COPD</b>	Severe	Severe	-	-
<b>Advanced HF</b>	Likely HTx or LVAD	Likely HTx or LVAD	Likely HTx or LVAD	Likely HTx or LVAD
<b>Other</b>	Previous ICD**	Previous ICD	Recent CRT (<3m)	Recent CRT (<3m)
<b>Primary outcomes</b>				
<b>Efficacy</b>	HF hospitalisation or urgent visits <sup>c</sup>	HF hospitalisation or urgent visits <sup>c</sup>	HF hospitalisations	All-cause death or HF hospitalisation or HF urgent visits <sup>c</sup>
<b>Safety</b>	Device-related complication Device failure	Device-related complication Device failure	Device-related complication Device failure	Device-related complication Device failure
<b>Haemodynamic changes</b>				
<b>PAPm AUC (mmHg-days)</b>	NA	NA	Treatment vs control -156 vs +33	Treatment vs control -793 vs -583
<b>PAPm AUC (mmHg-days)</b>	NA	NA	PH vs non-PH patients -568 vs -13.9	NA
<b>Change in ePAPd at six months (mmHg)</b>	Total population 1 (6)	Total population 0 (7)	NA	NA
<b>Medication changes during follow up</b>				
<b>All-drugs (per month-patient)</b>	Treatment vs control 5 vs 4.3 <sup>a</sup>	NA	Treatment vs control 1.5 vs 0.6	Treatment vs control 1.0 vs 0.6
<b>All-drugs (during follow up)</b>	Treatment vs control +28%	NA		NA
<b>All-drugs in PH patients (during follow up)</b>		NA	Treatment vs control 16.4 vs 6.9 (per patient)	NA
<b>Diuretic (per month-patient)</b>	Treatment vs control 2.4 vs 1.7 <sup>a</sup>	NA		NA
<b>Diuretic (during follow up)</b>	Treatment vs control All diuretics: +54%	NA	Treatment vs control Loop diuretic: +280%	NA
<b>Safety end-point</b>				
<b>Freedom from device related complication (%)</b>	91.5	90.5	98.6	99
<b>Outcomes results</b>				
<b>All-cause death Treatments vs controls</b>	HR [95%CI] 6 months NA	HR [95%CI] 12 months 0.77 [0.29-2.06]	HR [95%CI] 6 months 0.77 [0.39-1.51]  18 months 0.80 [0.56-1.15]	HR [95%CI] 12 months 1.09 [0.70-1.70]
<b>HF Hospitalisation Treatments vs controls</b>	HR [95%CI] 6 months 0.64 [0.42-0.97]	HR [95%CI] 12 months 0.99 [0.59-1.65]	HR [95%CI] 6 months 0.72 [0.61-0.85] avg 15 months 0.63 [0.52-0.77] avg 18 months 0.67 [0.56-0.80]	HR [95%CI] 12 months 0.83 [0.68-1.01]

AUC area under the curve, BMI body mass index, CKD chronic kidney disease, COPD chronic obstructive pulmonary disease, CRT cardiac resynchronization therapy, eGFR estimated glomerular filtration rate, HF heart failure, HFH heart failure hospitalisation, HR hazard ratio, HTx heart transplantation, ICD implantable cardiac defibrillator, LVAD left ventricular assist device, NYHA New York Heart Association, ePAPd estimated diastolic pulmonary artery pressure, PAPm pulmonary artery mean pressure, US United States

<sup>a</sup>Only participants but not the investigators were blinded

<sup>b</sup>Patients without previous heart failure hospitalisation meet inclusion criteria if they report elevated natriuretic peptides in the 30 days prior to the consent (prespecified thresholds defined brain-type natriuretic peptide ≥ 250 pg/ml or amino-terminal pro-brain natriuretic peptide values ≥ 1000 pg/ml)

<sup>c</sup>If not compatible with the monitoring device

<sup>d</sup>Emergency room access evaluations following by intravenous diuretic therapy

<sup>e</sup>These data refer only to the HFpEF cohort




**Table 2** (continued)

**A Heart Failure Hospitalisation**

Study Id	Follow up	nr of events		nr of patients	
		(Treatment)	(Treatment)	(Control)	(Control)
CHAMPION	18 months	182	270	279	280
COMPASS-HF	6 months	72	134	99	140
GUIDE-HF	12 months	185	497	225	503
REDUCEhf	12 months	72	202	78	198


Heterogeneity:  $I^2 = 29\%$ ,  $\tau^2 = 0.0077$ ,  $p = 0.24$   
 Test for overall effect:  $I_3 = -3.68$  ( $p = 0.03$ )



**B All-cause Mortality**

Study Id	Follow up	nr of events		nr of patients	
		(Treatment)	(Treatment)	(Control)	(Control)
CHAMPION	18 months	50	270	64	280
COMPASS-HF	6 months	13	134	11	140
GUIDE-HF	12 months	40	497	37	503
REDUCEhf	12 months	7	202	9	198

Heterogeneity:  $I^2 = 0\%$ ,  $\tau^2 = 0$ ,  $p = 0.59$   
 Test for overall effect:  $p = 0.48$



**Fig. 2** Primary outcomes: heart failure hospitalization (A) and all-cause mortality (B) at the longest follow-up available. Risk of bias was assessed for five domains: (D1) randomisation process, (D2) deviations from the intended interventions, (D3) missing outcome

data, (D4) measurement of the outcome, (D5) selection of the reported result (green indicates low risk of bias and yellow indicates some concerns of bias)

PAPm  $\geq 35$  mmHg at implantation had a fall in pressure (from  $44 \pm 7$  to  $37 \pm 10$  mmHg), whilst for those with a baseline PAPm  $< 25$  mmHg (from  $21 \pm 3$  to  $22 \pm 7$  mmHg) or 25–34 mmHg (from  $30 \pm 3$  to  $29 \pm 7$  mmHg) pressures were unchanged.

Of the 5,500 CardioMEMS implanted in the US during the first 3 years after FDA approval, the reported rate of adverse events was relatively low (155 events; 2.8%), including PA injury (28 reports, 6 of which culminated in death), 46 sensor malfunction or migration (1%), 15 (0.3%) bleeding or infection at the vascular access and 5 pulmonary embolism or device thrombosis [60]. Experience from Germany [61] and the UK [62] confirms that tailoring treatment according to PAP using CardioMEMS is safe and feasible also in the European health care systems.

Uncertainty remains about the cost-effectiveness of the CardioMEMS. Further research is required to estimate, more accurately, the financial sustainability at scale [63]. Whether these devices should be restricted to patients with PH is uncertain. The devices are expensive and therefore may not be cost effective in sick patients with a short life expectancy nor in well-controlled patients who may have few events. There will be a ‘sweet spot’ where patients are neither too well nor too sick to benefit [64].

Technological developments now allow pulmonary artery pressure to be combined with other vital signs, to allow clinicians to individualise treatments with greater precision and without the need of clinical visits [65].

Most of the circulating blood volume is contained in the highly compliant venous system, which might buffer the impact of an increased circulating volume on PAPm. The CardioMEMS device can measure PCWP, which reflect left atrial pressure, but it appears the snapshots that the device takes may be less reliable and therefore treatment recommendations are not based on them. Devices implanted in the atrial septum to measure left atrial pressure are being investigated [66]. Monitoring venous capacity by ultrasound or other means might be an even better approach to detect and correct haemodynamic problems (both under- and over-filling) than measuring PAP [67, 68].

**Limitations**

We were only able to access to published information, and not to individual patient data, which precluded more detailed analysis. Additional limitations include the heterogeneity of the devices used in the trials and changes in practice

and patient demographics over time (the first patients were enrolled in COMPASS-HF in 2003, in CHAMPION in 2007 and in GUIDE-HF in 2018); patients in GUIDE-HF were, on average, a decade older than in CHAMPION (see supplementary Table S1).

## Conclusions

Monitoring pulmonary artery pressure in patients with heart failure reduces the risk of total heart failure hospitalisations, but not mortality. The results of our meta-analysis not only support recently updated professional guidelines but also highlight the need for further research before recommending widespread use of these currently costly technologies. Better patient selection, better patient engagement and education, better therapeutic algorithms, more ambitious haemodynamic targets and more effective and well-tolerated interventions to achieve them could yet make haemodynamic monitoring a cornerstone of care for patients with heart failure.

Further research is required to implement these therapeutic strategies and to identify patients more likely to benefit, thereby justifying the additional costs.

**Supplementary Information** The online version contains supplementary material available at <https://doi.org/10.1007/s00392-022-02104-0>.

**Acknowledgements** AI is supported by a grant from Fondazione Enrico ed Enrica Sovena (Rome, Italy). PM is supported by the British Heart Foundation (BHF) [grant PG/19/84/34771, FS/19/56/34893A; PG/21/10541, PG/21/10634]; EC is supported by a European Society of Cardiology Research Grant and the Italian Ministry of University and Research (MIUR) PRIN 2017 [2017NKB2N4\_003].

**Funding** None.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

## References

- Pellicori P, Cleland JG, Zhang J, Kallvikbacka-Bennett A, Urbinati A, Shah P et al (2016) Cardiac dysfunction, congestion and loop diuretics: their relationship to prognosis in heart failure. *Cardiovasc Drugs Ther* 6:599–609. <https://doi.org/10.1007/s10557-016-6697-7>
- Gheorghiane M, Follath F, Ponikowski P, Barsuk JH, Blair JEA, Cleland JG et al (2010) Assessing and grading congestion in acute heart failure: a scientific statement from the acute heart failure committee of the heart failure association of the European Society of Cardiology and endorsed by the European Society of Intensive Care Medicine. *Eur J Heart Fail* 12:423–433. <https://doi.org/10.1093/eurjhf/hfq045>
- Felker GM, Anstrom KJ, Adams KF, Ezekowitz JA, Fiuzat M, Houston-Miller N et al (2017) Effect of natriuretic peptide-guided therapy on hospitalization or cardiovascular mortality in high-risk patients with heart failure and reduced ejection fraction: a randomized clinical trial. *JAMA* 318:713–720. <https://doi.org/10.1001/jama.2017.10565>
- Maisel A, Barnard D, Jaski B, Frivold G, Marais J, Azer M et al (2013) Primary results of the HABIT trial (heart failure assessment with BNP in the home). *J Am Coll Cardiol* 61(16):1726–1735. <https://doi.org/10.1016/j.jacc.2013.01.052> (Epub 2013 Mar 26. PMID: 23500322)
- Massari F, Scicchitano P, Iacoviello M, Passantino A, Guida P, Sanasi M et al (2019) Multiparametric approach to congestion for predicting long-term survival in heart failure. *J Cardiol* 75:47–52. <https://doi.org/10.1016/j.jcc.2019.05.017>
- Damy T, Goode KM, Kallvikbacka-Bennett A, Lewinter C, Hobkirk J, Nikitin NP et al (2010) Determinants and prognostic value of pulmonary arterial pressure in patients with chronic heart failure. *Eur Heart J* 31:2280–2290. <https://doi.org/10.1093/eurheartj/ehq245>
- Braunschweig F, Linde C, Eriksson MJ, Hofman-Bang C, Rydén L (2002) Continuous hemodynamic monitoring during withdrawal of diuretics in patients with congestive heart failure. *Eur Heart J* 23:59–69. <https://doi.org/10.1053/euhj.2001.2690>
- Humbert M, Kovacs G, Hoepfer MM, Badagliacca R, Berger RMF, Brida M et al (2022) ESC/ERS Scientific Document Group. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. *Eur Respir J*. <https://doi.org/10.1183/13993003.00879-2022>
- Kovacs G, Berghold A, Scheidl S, Olschewski H (2009) Pulmonary arterial pressure during rest and exercise in healthy subjects: a systematic review. *Eur Respir J* 34:888–894. <https://doi.org/10.1183/09031936.00145608>
- Maron BA, Hess E, Maddox TM, Opatowsky AR, Tedford RJ, Lahm T et al (2016) Association of borderline pulmonary hypertension with mortality and hospitalization in a large patients cohort: insights from the VA-CART program. *Circulation* 113:1240–1248. <https://doi.org/10.1161/CIRCULATIONAHA.115.020207>
- Augustine DX, Coates-Bradshaw LD, Willis J, Harkness A, Ring L, Grapsa J et al (2018) Echocardiographic assessment of pulmonary hypertension: a guideline protocol from the British Society of Echocardiography. *Echo Res Pract* 3:11–24. <https://doi.org/10.1530/ERP-17-0071>
- Greiner S, Jud A, Aurich M, Hess A, Hilbel T, Hardt S et al (2014) Reliability of non invasive assessment of systolic pulmonary artery pressure by Doppler echocardiography compared to right heart catheterization: analysis in a large patient population. *J Am Heart Assoc Cardiovasc Cerebrovasc Dis* 3:e001103. <https://doi.org/10.1161/JAHA.114.001103>
- Zile MR, Bennett TD, Sutton MJ, Cho YK, Adamson PB, Aaron MF et al (2008) Transition from chronic compensated to acute decompensated heart failure: pathophysiological insights obtained from continuous monitoring of intracardiac pressures. *Circulation* 118:1433–1441. <https://doi.org/10.1161/CIRCULATIONAHA.108.783910>
- Assad TR, Hemnes AR, Larkin EK, Glazer AM, Xu M, Wells QS et al (2016) Clinical and biological insights into combined post- and pre-capillary pulmonary hypertension. *J Am Coll Cardiol*. 68(23):2525–2536. <https://doi.org/10.1016/j.jacc.2016.09.942> (PMID: 27931609; PMCID: PMC5157701)

15. Al-Omary MS, Sugito S, Boyle AJ, Sverdlow AL, Collins NJ (2020) Pulmonary hypertension due to left heart disease: diagnosis, pathophysiology, and therapy. *Hypertension* 75(6):1397–1408. <https://doi.org/10.1161/HYPERTENSIONAHA.119.14330> (Epub 2020 Apr 27, PMID: 32336230)
16. Damy T, Hobkirk J, Walters M, Ciobanu A, Rigby AS, Kallvikbacka-Bennett A et al (2015) Development of a human model for the study of effects of hypoxia, exercise, and sildenafil on cardiac and vascular function in chronic heart failure. *J Cardiovasc Pharmacol* 66(3):229–238. <https://doi.org/10.1097/FJC.0000000000000262> (PMID: 25874853)
17. Guazzi M, Naeije R (2017) Pulmonary hypertension in heart failure: pathophysiology, pathobiology, and emerging clinical perspectives. *J Am Coll Card* 69:1718–1734. <https://doi.org/10.1016/j.jacc.2017.01.051>
18. Maron BA, Kovasc G, Vaidya A, Bhatt DL, Nishimura RA, Mak S et al (2020) Cardiopulmonary hemodynamic in pulmonary hypertension and heart failure. *J Am Coll Card* 22:2671–2681. <https://doi.org/10.1016/j.jacc.2020.10.007>
19. Shah AM, Shah SJ, Anand IS, Sweitzer NK, O'Meara E, Heitner JF et al (2014) Cardiac structure and function in heart failure with preserved ejection fraction: baseline findings from the echocardiographic study of the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial. *Circ Heart Fail* 7:104–115. <https://doi.org/10.1016/j.jacc.2016.07.763>
20. Miller WL, Grill DE, Borlaug BA (2013) Clinical features, hemodynamics, and outcomes of pulmonary hypertension due to chronic heart failure with reduced ejection fraction. *JACC Heart Fail* 1:290–299. <https://doi.org/10.1016/j.jchf.2013.05.001>
21. Zile MR, Gottdiener JS, Hetzel SJ, McMurray JJ, Komajda M, McKelvie R et al (2011) Prevalence and significance of alterations in cardiac structure and function in patients with heart failure and a preserved ejection fraction. *Circulation* 124:2491–2501. <https://doi.org/10.1161/CIRCULATIONAHA.110.011031>
22. Damy T, Kallvikbacka-Bennett A, Goode K, Khaleva O, Lewinter C, Hobkirk J et al (2012) Prevalence of, associations with, and prognostic value of tricuspid annular plane systolic excursion (TAPSE) among out-patients referred for the evaluation of heart failure. *J Card Fail* 18:216–225. <https://doi.org/10.1016/j.cardfail.2011.12.003>
23. Leung CC, Moondra V, Catherwood E, Andrus BW (2010) Prevalence and risk factors of pulmonary hypertension in patients with elevated pulmonary venous pressure and preserved ejection fraction. *Am J Cardiol* 206:284–286. <https://doi.org/10.1016/j.amjcard.2010.02.039>
24. Gorter TM, Hoendermis ES, Veldhuisen DJ, Voors AA, Lam CSP, Geelhoed B et al (2016) Right ventricular dysfunction in heart failure with preserved ejection fraction: a systematic review and meta-analysis. *Eur J Heart Fail* 18:1472–1487. <https://doi.org/10.1002/ejhf.630>
25. Aronson D, Darawsha W, Atamna A, Kaplan M, Makhoul BF, Mutlak D et al (2013) Pulmonary hypertension, right ventricular function, and clinical outcome in acute decompensated heart failure. *J Card Fail* 19:665–671. <https://doi.org/10.1016/j.cardfail.2013.08.007>
26. Ghio S, Gavazzi A, Campana C, Inserra C, Klersy C, Sebastiani R et al (2001) Independent and additive prognostic value of right ventricular systolic function and pulmonary artery pressure in patients with chronic heart failure. *J Am Coll Card* 37:183–188. [https://doi.org/10.1016/s0735-1097\(00\)01102-5](https://doi.org/10.1016/s0735-1097(00)01102-5)
27. Borlaug BA, Blair J, Bergmann M, Bugger H, Burkhoff D, Bruch L et al (2022) Latent pulmonary vascular disease fundamentally alters the response to therapeutic atrial shunt device in heart failure. *Circulation*. <https://doi.org/10.1161/CIRCULATIONAHA.122.059486>
28. Wolsk E, Kaye DM, Komtebedde J, Shah SJ, Borlaug BA, Burkhoff D et al (2021) Determinants and consequences of heart rate and stroke volume response to exercise in patients with heart failure and preserved ejection fraction. *Eur J Heart Fail* 23:754–764. <https://doi.org/10.1002/ejhf.2146>
29. Lam CSP, Roger VL, Rodeheffer RJ, Borlaug BA, Enders FT, Redfield MM (2009) Pulmonary hypertension in heart failure with preserved ejection fraction: a community-based study. *J Am Coll Card* 13:1119–1126. <https://doi.org/10.1016/j.jacc.2008.11.051>
30. Binanay C, Califf RM, Hasselblad V, O'Connor CM, Shah MR, Sopko G et al (2005) ESCAPE investigators and ESCAPE study coordinators evaluation study of congestive heart failure and pulmonary artery catheterization effectiveness: the ESCAPE trial. *JAMA* 294:1625–1633. <https://doi.org/10.1001/jama.294.13.1625>
31. Shah MR, Hasselblad V, Stevenson LW, Binanay C, O'Connor CM, Sopko G et al (2005) Impact of the pulmonary artery catheter in critically ill patients: meta-analysis of randomized clinical trials. *JAMA* 294(13):1664–1670. <https://doi.org/10.1001/jama.294.13.1664> (PMID: 16204666)
32. Magalski A, Adamson P, Gadler F, Böehm M, Steinhaus D, Reynolds D et al (2002) Continuous ambulatory right heart pressure measurements with an implantable hemodynamic monitor: a multicentre 12-months follow up study of patients with chronic heart failure. *J Card Fail* 8:63–70. <https://doi.org/10.1054/jcaf.2002.32373>
33. Adamson PB, Conti JB, Smith AL, Abraham WT, Aaron MF, Aranda JM et al (2022) Reducing events in patients with chronic heart failure study design: continuous hemodynamic monitor with an implantable defibrillator. *Clin Cardiol* 30:567–575. <https://doi.org/10.1002/clc.20250>
34. Angermann CE, Assmus B, Anker SD, Brachmann J, Ertl G, Kohler F et al (2018) Safety and feasibility of pulmonary artery pressure-guided heart failure therapy: rationale and design of prospective CardioMEMS Monitoring Study for Heart Failure (MEMS-HF). *Clin Res Cardiol* 107:991–1002. <https://doi.org/10.1007/s00392-018-1281-8>
35. McDonagh TA, Metra M, Adamo M, Gardner RS, Baumhach A, Bohm M, ESC Scientific Document Group 2021 et al (2021) 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. *Eur Heart J* 42:3599–3726. <https://doi.org/10.1093/eurheartj/ehab368>
36. Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM et al (2022) 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. *Circulation*. <https://doi.org/10.1161/CIR.0000000000001063> (Epub ahead of print. PMID: 35363499)
37. Lindenfeld J, Zile MR, Desai AS, Bhatt K, Ducharme A, Horstmanshof D et al (2021) Haemodynamic-guided management of heart failure (GUIDE-HF): a randomised controlled trial. *Lancet* 398:991–1001. [https://doi.org/10.1016/S0140-6736\(21\)01754-2](https://doi.org/10.1016/S0140-6736(21)01754-2)
38. Abraham WT, Adamson PB, Bourge RC, Aaron MF, Costanzo MR, Stevenson LW, CHAMPION Trial Study Group et al (2011) Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: a randomised controlled trial. *Lancet* 377:658–666. [https://doi.org/10.1016/S0140-6736\(11\)60101-3](https://doi.org/10.1016/S0140-6736(11)60101-3)
39. Abraham WT, Stevenson LW, Bourge RC, Lindenfeld JA, Bauman JG, Adamson PB (2016) Sustained efficacy of pulmonary artery pressure to guide adjustment of chronic heart failure therapy: complete follow-up results from the CHAMPION randomised trial. *Lancet* 387:453–461. [https://doi.org/10.1016/S0140-6736\(15\)00723-0](https://doi.org/10.1016/S0140-6736(15)00723-0)

40. Givertz MM, Stevenson LW, Costanzo MR, Bourge RC, Bauman JG, Ginn G et al (2017) Pulmonary artery pressure-guided management of patients with heart failure and reduced ejection fraction. *J Am Coll Cardiol* 70:1875–1886. <https://doi.org/10.1016/j.jacc.2017.08.010>
41. Adamson PB, Abraham WT, Bourge RC, Costanzo MR, Hasan A, Yadav C et al (2014) Wireless pulmonary artery pressure monitoring guides management to reduce decompensation in heart failure with preserved ejection fraction. *Circ Heart Fail* 7:935–944. <https://doi.org/10.1161/CIRCHEARTFAILURE.113.001229>
42. Bourge RC, Abraham WT, Adamson PB, Aaron MF, Aranda JM Jr, Magalski A, COMPASS-HF Study Group et al (2008) Randomized controlled trial of an implantable continuous hemodynamic monitor in patients with advanced heart failure. *J Am Coll Card* 51:1073–1079. <https://doi.org/10.1016/j.jacc.2007.10.061>
43. Zile MR, Bourge RC, Bennet TD, Stevenson LW, Cho YK, Adamson PB et al (2008) Application of implantable hemodynamic monitoring in the management of patients with diastolic heart failure: a subgroup analysis of the COMPASS-HF trial. *J Card Fail* 14:816–823. <https://doi.org/10.1016/j.cardfail.2008.07.235>
44. Adamson PB, Gold MR, Bennett T, Bourge RC, Stevenson LW, Trupp R et al (2011) Continuous hemodynamic monitoring in patients with mild to moderate heart failure: results of the reducing decompensation events utilizing intracardiac pressures in patients with chronic heart failure (REDUCEhf) trial. *Congest Heart Fail* 17:248–254. <https://doi.org/10.1111/j.1751-7133.2011.00247>
45. Cleland JGF, Pellicori P (2021) To master heart failure, first master congestion. *Lancet* 398:935–936. [https://doi.org/10.1016/S0140-6736\(21\)01914-0](https://doi.org/10.1016/S0140-6736(21)01914-0)
46. Cowie MR, Cleland JGF (2022) The COVID-19 pandemic and heart failure: lessons from GUIDE-HF. *Eur Heart J* 43(27):2619–2621. <https://doi.org/10.1093/eurheartj/ehac226> (PMID: 35511076, PMCID: PMC9279113)
47. Zile MR, Bennett TD, El Hajj S, Kueffer FJ, Baicu CF, Abraham WT et al (2017) Intracardiac pressures measured using an implantable hemodynamic monitor. Relationship to mortality in patients with chronic heart failure. *Circ Heart Fail* 10:e003594. <https://doi.org/10.1161/CIRCHEARTFAILURE.116.003594>
48. Magalski A, Adamson P, Gadler F, Böehm M, Steinhaus D, Reynolds D et al (2002) Continuous ambulatory right heart pressure measurements with an implantable hemodynamic monitor: a multicenter, 12-month follow-up study of patients with chronic heart failure. *J Card Fail* 8:63–70. <https://doi.org/10.1054/jcaf.2002.32373>
49. Adamson PB, Magalski A, Braunschweig F, Böhm M, Reynolds D, Steinhaus D et al (2003) Ongoing right ventricular hemodynamics in heart failure: clinical value of measurements derived from an implantable monitoring system. *J Am Coll Cardiol* 41:565–571. [https://doi.org/10.1016/s0735-1097\(02\)02896-6](https://doi.org/10.1016/s0735-1097(02)02896-6)
50. Cleland JGF, Renjit A (2011) It makes SENSE to take a safer road. *Eur Heart J* 32:2225–2227. <https://doi.org/10.1093/eurheartj/ehrl20>
51. Zile MR, Desai AS, Costanzo MR, Ducharme A, Maisel A, Mehra MR et al (2022) The GUIDE-HF trial of pulmonary artery pressure monitoring in heart failure: impact of the COVID-19 pandemic. *Eur Heart J*. <https://doi.org/10.1093/eurheartj/ehac114> (Epub ahead of print. PMID: 35266003)
52. Mamazhakypov A, Hein L, Lother A (2021) Mineral receptors in pulmonary hypertension and right heart failure: from molecular biology to therapeutic targeting. *Pharmacol Ther* 1:107987. <https://doi.org/10.1016/j.pharmthera.2021.107987>
53. Tran JS, Havakuk O, McLeod JM, Hwang J, Kwong HY, Shavelle D et al (2021) Acute pulmonary pressure change after transition to sacubitril/valsartan in patients with heart failure reduced ejection fraction. *ESC Heart Fail* 8:1706–1710. <https://doi.org/10.1002/ehf2.13225>
54. Khan Z, Gholkar G, Tolia S, Cadeau H, Zughaib M (2018) Effect of sacubitril/valsartan on cardiac filling pressures in patients with left ventricular systolic dysfunction. *Int J Card* 271:169–173. <https://doi.org/10.1016/j.ijcard.2018.03.093>
55. Seferović PM, Coats AJS, Ponikowski P, Filippatos G, Huelsmann M, Jhund PS et al (2020) European Society of Cardiology/Heart Failure Association position paper on the role and safety of new glucose-lowering drugs in patients with heart failure. *Eur J Heart Fail* 22(2):196–213. <https://doi.org/10.1002/ejhf.1673> (Epub 2019 Dec 9. PMID: 31816162)
56. Mullens W, Martens P, Forouzan O, Dauw J, Vercammen J, Luwel E et al (2020) Effects of dapagliflozin on congestion assessed by remote pulmonary artery pressure monitoring. *ESC Heart Fail* 7:2071–2073. <https://doi.org/10.1002/ehf2.12850>
57. Nassif ME, Qintar M, Windsor SL, Jermyn R, Shavelle DM, Tang F et al (2021) Empagliflozin effects on pulmonary artery pressure in patients with heart failure: results from the EMBRACE-HF trial. *Circulation* 143:1673–1686. <https://doi.org/10.1161/CIRCULATIONAHA.120.052503>
58. Shavelle DM, Desai AS, Abraham WT, Bourge RC, Raval N, Rathman LD, CardioMEMS Post-Approval Study Investigators et al (2020) Lower rates of heart failure and all-cause hospitalisation during pulmonary artery pressure-guided therapy for ambulatory heart failure. *Circ Heart Fail* 13:e006863. <https://doi.org/10.1161/CIRCHEARTFAILURE.119.006863>
59. Heywood JT, Jermyn R, Shavelle D, Abraham WT, Bhimaraj A, Bhatt K et al (2017) Impact of practice-based management of pulmonary artery pressures in 2000 patients implanted with the CardioMEMS sensor. *Circulation* 135:1509–1517. <https://doi.org/10.1161/CIRCULATIONAHA.116.026184>
60. Vaduganathan M, DeFilippis EM, Fonarow GC, Butler J, Mehra MR (2017) Postmarketing adverse events related to the CardioMEMS HF system. *JAMA Cardiol* 2:1277–1279. <https://doi.org/10.1001/jamacardio.2017.3791>
61. Angermann CE, Assmus B, Anker SD, Asselbergs FW, Brachmann J, Brett ME et al (2020) Pulmonary artery pressure-guided therapy in ambulatory patients with symptomatic heart failure: the CardioMEMS European monitoring study for heart failure. *Eur J Heart Fail* 22:1891–1901. <https://doi.org/10.1002/ejhf.1943>
62. Cowie MR, Flett A, Cowburn P, Foley P, Chandrasekaran B, Loke I et al (2022) Real-world evidence in a national health service: results of the UK CardioMEMS HF System Post-Market Study. *ESC Heart Fail* 9:48–56. <https://doi.org/10.1002/ehf2.13748>
63. Sandhu AT, Goldhaber-Fiebert JD, Owens DK, Turakhia MP, Kaiser DW, Heidenreich PA (2016) Cost effectiveness of implantable pulmonary artery pressure monitoring in chronic heart failure. *J Am Coll Cardiol HF* 4:368–375. <https://doi.org/10.1016/j.jchf.2015.12.015>
64. Cleland JGF, Tavazzi L, Daubert JC, Tageldien A, Freemantle N (2009) Cardiac resynchronization therapy: are modern myths preventing appropriate use? *J Am Coll Cardiol* 53:608–611. <https://doi.org/10.1016/j.jacc.2008.10.040>
65. Mullens W, Sharif F, Dupont M, Rothman AMK, Wijns W (2020) Digital health care solution for proactive heart failure management with the Cordella Heart Failure System: results of the SIRONA first-in-human study. *Eur J Heart Fail* 22(10):1912–1919. <https://doi.org/10.1002/ejhf.1870> (Epub 2020 May 31, PMID: 32476191; PMCID: PMC7687200)

66. Perl L, Meerkin D, D'amario D, Avraham BB, Gal TB, Weitsman T et al (2022) The V-LAP system for remote left atrial pressure monitoring of patients with heart failure: remote left atrial pressure monitoring. *J Card Fail* S1071–9164(22):00004–00005. <https://doi.org/10.1016/j.cardfail.2021.12.019>
67. Ivey-Miranda JB, Wetterling F, Gaul R, Sheridan S, Asher JL, Rao VS et al (2021) Changes in inferior vena cava represents a more sensitive metric than change in filling pressures during experimental manipulation of intravascular volume and tone. *Eur J Heart Fail*. <https://doi.org/10.1002/ejhf.2395>
68. Pellicori P, Platz E, Dauw J, Ter Maaten JM, Martens P, Pivetta E et al (2021) Ultrasound imaging of congestion in heart failure: examinations beyond the heart. *Eur J Heart Fail* 23(5):703–712. <https://doi.org/10.1002/ejhf.2032>